{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=leflunomide&page=2",
    "query": {
      "intervention": "leflunomide",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=leflunomide&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T00:09:03.478Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01749787",
      "title": "Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "PRTX-100 at 1.5 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "PRTX-100 at 3.0 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "PRTX-100 at 6.0 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "PRTX-100 at 12.0 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "PRTX-100 at 240 mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PRTX-100 at 420 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Protalex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2012-11",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Coeur d'Alene, Idaho + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Anderson",
          "state": "Indiana"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01749787"
    },
    {
      "nct_id": "NCT00124982",
      "title": "Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)",
          "type": "DRUG"
        },
        {
          "name": "Anti-Tumor Necrosing Factor (TNF) Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1286,
      "start_date": "2005-04",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2012-02-27",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 114,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00124982"
    },
    {
      "nct_id": "NCT00579878",
      "title": "Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate-Sulfasalazine-Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide-Sulfasalazine-Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 69,
      "start_date": "2001-03-27",
      "completion_date": "2010-03-11",
      "has_results": true,
      "last_update_posted_date": "2023-10-02",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00579878"
    },
    {
      "nct_id": "NCT02451748",
      "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Lab Work",
          "type": "OTHER"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Medrol",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone",
          "type": "DRUG"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "humira",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-08",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451748"
    },
    {
      "nct_id": "NCT02057250",
      "title": "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RA"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Auto-Injector Device (AID)",
          "type": "DEVICE"
        },
        {
          "name": "Pre-filled Syringe (PFS)",
          "type": "DEVICE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2014-03",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-06-20",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 31,
      "location_summary": "Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057250"
    },
    {
      "nct_id": "NCT07138898",
      "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatic Disease"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Belimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anakinra",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ixekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bimekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ustekinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Guselkumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Risankizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-12-12",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07138898"
    },
    {
      "nct_id": "NCT04725422",
      "title": "CHronic Nonbacterial Osteomyelitis International Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Nonbacterial Osteomyelitis",
        "Chronic Recurrent Multifocal Osteomyelitis"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Pamidronate",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "NSAID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2018-08-01",
      "completion_date": "2050-08",
      "has_results": false,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04725422"
    },
    {
      "nct_id": "NCT00720798",
      "title": "An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Disease-modifying anti-rheumatic drugs",
          "type": "DRUG"
        },
        {
          "name": "Non-steroidal anti-inflammatory drugs",
          "type": "DRUG"
        },
        {
          "name": "Oral corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2067,
      "start_date": "2005-09",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 138,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 119 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720798"
    },
    {
      "nct_id": "NCT00834405",
      "title": "Leflunomide 20 mg Tablets, Non-Fasting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ARAVA® 20 mg tablets",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide 20 mg Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2002-04",
      "completion_date": "2002-05",
      "has_results": true,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 2,
      "location_summary": "Saint Charles, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834405"
    },
    {
      "nct_id": "NCT01313208",
      "title": "Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "DMARD Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 210,
      "start_date": "2011-03",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2017-02-09",
      "last_synced_at": "2026-09-23T00:09:03.478Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313208"
    }
  ]
}